Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-κB signaling pathway

Oncogene

Volumn 37, Issue 23, 2018, Pages 3070-3087

  Jin, Peng ^a   Shin, Seung Hyun ^a   Chun, Yang Sook ^a   Shin, Hyun Woo ^a   Shin, Yong Jae ^b,c   Lee, Yeri ^b   Kim, Donggeon ^b   Nam, Do Hyun ^b,c   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CHEMOKINE RECEPTOR CCR6; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRIGEL; PROTEIN; WORTMANNIN; CCL20 PROTEIN, HUMAN; CCR6 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN TISSUE; CELL HYPOXIA; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CHEMOKINE CCL20; CHEMOKINE CXCL12; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE, INBRED BALB C; NF-KAPPA B; RECEPTORS, CCR6; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85043689290     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-018-0182-7     Document Type: Article

References (34)

1. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232:165-77.
2. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60:502-14.
3. Lorger M. Tumor microenvironment in the brain. Cancers. 2012;4:218-43.
4. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9(Suppl 5):10-17.
5. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12:9-22.
6. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998;8:588-94.
7. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70:1469-80.
8. O'Brien ER, Howarth C, Sibson NR. The role of astrocytes in CNS tumors: pre-clinical models and novel imaging approaches. Front Cell Neurosci. 2013;7:40.
9. Placone AL, Quinones-Hinojosa A, Searson PC. The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. Tumour Biol. 2016;37:61-69.
10. Rath BH, Fair JM, Jamal M, Camphausen K, Tofilon PJ. Astrocytes enhance the invasion potential of glioblastoma stem-like cells. PLoS ONE. 2013;8:e54752.
11. Lee YM, Lim JH, Yoon H, Chun YS, Park JW. Antihepatoma activity of chaetocin due to deregulated splicing of hypoxiainducible factor 1alpha pre-mRNA in mice and in vitro. Hepatology. 2011;53:171-80.
12. Ayrapetov MK, Xu C, Sun Y, Zhu K, Parmar K, D'Andrea AD. Activation of Hif1alpha by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity. PLoS ONE. 2011;6:e26064.
13. Gorlach A, Bonello S. The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem J. 2008;412:e17-e19.
14. Zeng W, Chang H, Ma M, Li Y. CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol. 2014;97:184-90.
15. Marsigliante S, Vetrugno C, Muscella A. CCL20 induces migration and proliferation on breast epithelial cells. J Cell Physiol. 2013;228:1873-83.
16. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 2005;7:134-53.
17. Gagliano N, Costa F, Cossetti C, Pettinari L, Bassi R, Chiriva-Internati M. Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. Oncol Rep. 2009;22:1349-56.
18. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005;15:297-310.
19. Yang L, Lin C, Wang L, Guo H, Wang X. Hypoxia and hypoxiainducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res. 2012;318:2417-26.
20. Mendez O, Zavadil J, Esencay M, Lukyanov Y, Santovasi D, Wang SC. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer. 2010;9:133.
21. Giannopoulou E, Ravazoula P, Kalofonos H, Makatsoris T, Kardamakis D. Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study. Vivo. 2006;20:421-5.
22. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, Boviatsis E. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol. 2004;30:267-78.
23. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409-26.
24. McColl SR. Chemokines and dendritic cells: a crucial alliance. Immunol Cell Biol. 2002;80:489-96.
25. Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009;125:741-5.
26. Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2012;16:828-36.
27. Wang L, Qin H, Li L, Zhang Y, Tu Y, Feng F. Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas. Med Oncol. 2012;29:3491-7.
28. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
29. Okamoto T, Sanda T, Asamitsu K. NF-kappa B signaling and carcinogenesis. Curr Pharm Des. 2007;13:447-62.
30. Ambrosini E, Columba-Cabezas S, Serafini B, Muscella A, Aloisi F. Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia. 2003;41:290-300.
31. Li R, Xu W, Chen Y, Qiu W, Shu Y, Wu A. Raloxifene suppresses experimental autoimmune encephalomyelitis and NFkappaB-dependent CCL20 expression in reactive astrocytes. PLoS ONE. 2014;9:e94320.
32. Battaglia F, Delfino S, Merello E, Puppo M, Piva R, Varesio L. Hypoxia transcriptionally induces macrophage-inflammatory protein-3alpha/CCL-20 in primary human mononuclear phagocytes through nuclear factor (NF)-kappaB. J Leukoc Biol. 2008;83:648-62.
33. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391-403.
34. Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ. Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in glioblastoma stem-like cells. Cell Rep. 2015;13:2425-39.